StockWatch
·
MEGASOFT LTD. · QQ2 FY-2027 · THE CALL

Consolidated growth masks standalone revenue cliff; guidance credibility unproven

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsSIGMAADVMEGASOFT LTD.12 Nov 2026 · 6 min read
Verdict

Hold

confidence 3/10

Credibility

Grade C

No prior guidance filed. Consolidated metrics (₹417 Cr) vs delivered standalone (₹46.5 Cr) create 9x unexplained variance.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Order book and M&A strategy suggest multi-year structural upside (FY27-FY28 margin expansion via UK/India integration, defense exports ramp). BUT standalone revenue ₹46.5 Cr contradicts mgmt's consolidated ₹417 Cr claim by 9x; QoQ decline -87.6% vs claimed +11% growth raises critical credibility questions. Guidance unproven; no track record. Risk: consolidation adjustments, execution delays in facilities, margin headwinds.

₹46.5 Cr

Revenue · +null% YoY

₹14.9 Cr

Reported PAT · +2559.8% YoY

Expanding

Margins · vs guidance: Contradicted

Did the claims hold up?

Management's claims vs. the numbers

Q2 operational revenue INR417 Cr, 11.43% QoQ growth from 374 Cr Q1

MISS

Delivered Q2 revenue ₹46.5 Cr, down 87.6% QoQ

Q2 PAT INR48.6 Cr (ex-associates), up from Q1's 35.41 Cr

MISS

Delivered Q2 PAT ₹14.9 Cr; standalone profitability far below claim

Order book ~10,000+ Cr, 90% international, strong visibility

Unverified

Unverified from filings; management provided no segment breakdowns despite analyst requests

FY27 revenue guidance INR1,900-2,000 Cr

OVERSTATED

Guidance not yet testable; prior guidance none on record. Standalone trajectory suggests target wildly optimistic.

Earnings quality

What changed since the last call

Deltas vs. the prior call

Order book consolidation

Upgrade

H1 FY27 new order wins ₹3,915 Cr (vs no prior guidance); defense order book ₹2,700 Cr executable over 5-7 years.

Capacity utilization baseline

Downgrade

Aerospace only 15% utilized, ammunition 20%, post-acquisition. Implies prior standalone ops much smaller.

Profitability scale

Downgrade

Standalone Q2 PAT ₹14.9 Cr vs mgmt claim ₹48.6 Cr; acquisition contribution not separated.

The Q&A

Moderate. Analysts pressed on capex requirements (answered: adequate, no more capex needed), manufacturing facility split (answered: 30-70 UK-India split), and capacity utilization (answered: 10-15% CCT post-ramp). Management withheld customer breakdowns (NDA), facility-level financials, and acquisition details. Confidence in Q&A: neutral-to-cautious; evasion on key metrics.

The exchanges that mattered

Post-acquisition capex & margins — Nilesh Soni, Haitong Securities

Answered

₹8-9M capex invested; improvements in on-time-in-full (OTIFs 65→97%), buffer stock, equipment kits. 200% per-quarter improvement in UK EBITDA margin.

M107 shells revenue recognition — Ronak Singhvi, NAFA Asset Managers

Answered

85% already recognized in Q1-Q2; 15% completion in Q3. Supplied to Indrajal for 155mm shells order.

Defense manufacturing facility capacity — Dipen Vakil, Phillip Capitals

Answered

Aerospace 15%, ammunition ~20%. No more capex; facility good for next few years. Sri City ramp to 50-60% by Q4, 100% by FY29.

Aerospace order book delivery cadence — Dipen Vakil, Phillip Capitals

Partial

Long-term executable contracts, stable high-visibility. UK execution 15-20% annual growth, 15% per quarter ramp.

Fundraise purpose and timing — Rajesh Joseph, Individual Investor

Answered

Fuel M&A growth; expected Q4 close, subject to shareholder approval, etcetera.

Defense vs aerospace revenue split — Jai Mendratta, Nirmal Bang

Partial

Yes, domestic defense strategic focus; will continue to grow. Defense order book ₹2,700 Cr.

Export revenue and geographic footprint — Varun Kulkarni, InCred Capital

Partial

~90% revenue export between UK and India. Cannot disclose customer breakdowns due to NDAs.

Aeropsace margin expansion mechanics — Tejash, T&J Investments

Partial

Work transfer from UK to India, automation capex payoff, scale in India. 25-30% EBITDA margin by FY28 possible.

CCT facility utilization forecast — Tejash, T&J Investments

Answered

10-15% post-ramp start. Every quarter ~10% increase. 50-60% by FY28 end.

Debt and working capital — Devang, Spark PMS

Answered

Debt ~₹80 Cr, mostly working capital. Term borrowings low; payback Jan-Dec FY27 per agreement. Debt-light balance sheet.

Guidance

Forward guidance and management's confidence

FY27 revenue ₹1,900-2,000 Cr (consolidated target)

Low

No prior guidance to validate. Requires H2 sustain of ₹417 Cr run-rate (8 quarters forward at ~₹500 Cr per quarter). Standalone trajectory suggests external reliance on M&A consolidation only.

EBITDA margin ~20% FY27; expand 200-400 bps by FY27 end, 400-600 bps by FY28 end (25-30% aerospace target)

Medium

Mechanism credible (UK automation capex payoff, India work transfer, scale). But execution risk high on work-to-India logistics & labor ramp. Current aerospace EBITDA 22-30% range; defense margins higher.

No additional capex required; prior investments sufficient for next few years

High

Sri City facility built; UK capex (automation) already deployed. Only work-transfer & incremental shifts needed.

Risks the call surfaced

Ranked by how much they should concern a holder

Revenue reporting discrepancy

High

Mgmt claims ₹417 Cr Q2 revenue; delivered standalone ₹46.5 Cr. 9x gap suggests heavy M&A reliance and weak organic core.

Standalone revenue contraction

High

Q2 standalone revenue ₹46.5 Cr down 87.6% QoQ (implied Q1 ~₹354 Cr). Suggests core Indian operations under stress or major project completion skew.

M&A integration execution

High

Nasmyth was in financial distress pre-acquisition; Bromford integration unproven. Target margin expansion (200-400 bps FY27, 400-600 bps FY28) depends on successful automation, work transfer, cultural fit.

Customer concentration

High

90% of revenue from export contracts with major OEMs (Rolls-Royce, Airbus, Lockheed, BAE Systems). Loss of single customer or contract deferral has outsized impact.

Capex deployment risk on Sri City

Medium

Sri City facility (operational Sept 2026) targeting 50-60% utilization by FY28. If order intake fails or ramp stutters, capex stranding and margin compression.

Fundraise delay or shortfall

Medium

₹3,000 Cr fundraise for inorganic growth expected Q4 close. Shareholder approval, market conditions, regulatory delays could derail M&A pipeline.

Management

Score 6/10. Confident on strategy and order book, but evasive on segment metrics. Withheld customer breakdowns (NDA), facility-level financials, and capex detail. Avoided detailed P&L reconciliation between standalone and consolidated. Mixed. Achieved OTIF ramp (65→97% Nasmyth), on-time delivery to Rolls-Royce, repeat orders. But Q2 standalone revenue ₹46.5 Cr contradicts consolidated ₹417 Cr claim; execution on India manufacturing scale still nascent (Sri City Sept 2026 start).

What to watch next
  • 1 · Q3/Q4 FY27

    Defense order ramp-up expected Q3-Q4; new Indrajal BSF contract delivery

  • 2 · H2 FY27

    Sri City facility capacity ramp to 50-60%; 155mm shells production scaling

  • 3 · Q4 FY27

    M&A completion expected (target Q4); ₹3000 Cr fundraise ongoing

Risk: consolidation adjustments, execution delays in facilities, margin headwinds.

Informational and educational content only. Not investment advice.